Literature DB >> 26140734

Mesenchymal stem cells do not exert direct beneficial effects on CNS remyelination in the absence of the peripheral immune system.

Laura Salinas Tejedor1, Gabriel Berner2, Kristin Jacobsen2, Viktoria Gudi1, Nicole Jungwirth3, Florian Hansmann3, Stefan Gingele2, Chittappen K Prajeeth2, Wolfgang Baumgärtner3, Andrea Hoffmann4, Thomas Skripuletz2, Martin Stangel5.   

Abstract

Remyelination is the natural repair mechanism in demyelinating disorders such as multiple sclerosis (MS) and it was proposed that it might protect from axonal loss. For unknown reasons, remyelination is often incomplete or fails in MS lesions and therapeutic treatments to enhance remyelination are not available. Recently, the transplantation of exogenous mesenchymal stem cells (MSC) has emerged as a promising tool to enhance repair processes. This included the animal model experimental autoimmune encephalomyelitis (EAE), a commonly used model for the autoimmune mechanisms of MS. However, in EAE it is not clear if the beneficial effect of MSC derives from a direct influence on brain resident cells or if this is an indirect phenomenon via modulation of the peripheral immune system. The aim of this study was to determine potential regenerative functions of MSC in the toxic cuprizone model of demyelination that allows studying direct effects on de- and remyelination without the influence of the peripheral immune system. MSC from three different species (human, murine, canine) were transplanted either intraventricularly into the cerebrospinal fluid or directly into the lesion of the corpus callosum at two time points: at the onset of oligodendrocyte progenitor cell (OPC) proliferation or the peak of OPC proliferation during cuprizone induced demyelination. Our results show that MSC did not exert any regenerative effects after cuprizone induced demyelination and oligodendrocyte loss. During remyelination, MSC did not influence the dynamics of OPC proliferation and myelin formation. In conclusion, MSC did not exert direct regenerative functions in a mouse model where peripheral immune cells and especially T lymphocytes do not play a role. We thus suggest that the peripheral immune system is required for MSC to exert their effects and this is independent from a direct influence of the central nervous system.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corpus callosum; Cuprizone; Intraventricular; MS; MSC

Mesh:

Substances:

Year:  2015        PMID: 26140734     DOI: 10.1016/j.bbi.2015.06.024

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  12 in total

1.  Mesenchymal Stem Cells Form 3D Clusters Following Intraventricular Transplantation.

Authors:  Nicole Jungwirth; Laura Salinas Tejedor; Wen Jin; Viktoria Gudi; Thomas Skripuletz; Veronika Maria Stein; Andrea Tipold; Andrea Hoffmann; Martin Stangel; Wolfgang Baumgärtner; Florian Hansmann
Journal:  J Mol Neurosci       Date:  2018-04-28       Impact factor: 3.444

Review 2.  Achievements and obstacles of remyelinating therapies in multiple sclerosis.

Authors:  Martin Stangel; Tanja Kuhlmann; Paul M Matthews; Trevor J Kilpatrick
Journal:  Nat Rev Neurol       Date:  2017-11-17       Impact factor: 42.937

3.  The Effect of Stereotactic Injections on Demyelination and Remyelination: a Study in the Cuprizone Model.

Authors:  Laura Salinas Tejedor; Tanja Wostradowski; Stefan Gingele; Thomas Skripuletz; Viktoria Gudi; Martin Stangel
Journal:  J Mol Neurosci       Date:  2017-01-26       Impact factor: 3.444

4.  Mesenchymal stem cells attenuate MRI-identifiable injury, protect white matter, and improve long-term functional outcomes after neonatal focal stroke in rats.

Authors:  Cindy T van Velthoven; Mark Dzietko; Michael F Wendland; Nikita Derugin; Joel Faustino; Cobi J Heijnen; Donna M Ferriero; Zinaida S Vexler
Journal:  J Neurosci Res       Date:  2016-10-26       Impact factor: 4.164

5.  Mesenchymal stem cells require the peripheral immune system for immunomodulating effects in animal models of multiple sclerosis.

Authors:  Laura Salinas Tejedor; Thomas Skripuletz; Martin Stangel; Viktoria Gudi
Journal:  Neural Regen Res       Date:  2016-01       Impact factor: 5.135

6.  Intracerebral transplantation of interleukin 13-producing mesenchymal stem cells limits microgliosis, oligodendrocyte loss and demyelination in the cuprizone mouse model.

Authors:  Debbie Le Blon; Caroline Guglielmetti; Chloé Hoornaert; Alessandra Quarta; Jasmijn Daans; Dearbhaile Dooley; Evi Lemmens; Jelle Praet; Nathalie De Vocht; Kristien Reekmans; Eva Santermans; Niel Hens; Herman Goossens; Marleen Verhoye; Annemie Van der Linden; Zwi Berneman; Sven Hendrix; Peter Ponsaerts
Journal:  J Neuroinflammation       Date:  2016-11-09       Impact factor: 8.322

7.  Intravenous transplantation of mouse embryonic stem cells attenuates demyelination in an ICR outbred mouse model of demyelinating diseases.

Authors:  Kidsadagon Pringproa; Anucha Sathanawongs; Chananthida Khamphilai; Sarocha Sukkarinprom; Apichart Oranratnachai
Journal:  Neural Regen Res       Date:  2016-10       Impact factor: 5.135

Review 8.  Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer's Disease.

Authors:  Ankit Tandon; Sangh Jyoti Singh; Rajnish Kumar Chaturvedi
Journal:  Biomed Res Int       Date:  2018-07-12       Impact factor: 3.411

9.  Effect of Multiple Intraperitoneal Injections of Human Bone Marrow Mesenchymal Stem Cells on Cuprizone Model of Multiple Sclerosis

Authors:  Mohsen Marzban; Kazem Mousavizadeh; Masoomeh Bakhshayesh; Nasim Vousooghi; Gelareh Vakilzadeh; Anahita Torkaman-Boutorabi
Journal:  Iran Biomed J       Date:  2018-02-07

10.  Recipient Glycemic Micro-environments Govern Therapeutic Effects of Mesenchymal Stem Cell Infusion on Osteopenia.

Authors:  Bing-Dong Sui; Cheng-Hu Hu; Chen-Xi Zheng; Yi Shuai; Xiao-Ning He; Ping-Ping Gao; Pan Zhao; Meng Li; Xin-Yi Zhang; Tao He; Kun Xuan; Yan Jin
Journal:  Theranostics       Date:  2017-03-06       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.